Abivertinib clinical trials
Also written AC0010, AC0010MA and avitinib.
How each study uses abivertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 2
Hangzhou ACEA Pharmaceutical Research Co., Ltd. (7) · Sorrento Therapeutics, Inc. (3) · ACEA Therapeutics, Inc. (1) · Guangdong Association of Clinical Trials (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Abiraterone (1) · Crizotinib (1) · Ensartinib (1) · Tucidinostat (1) · Shr-1258 dimaleate (1) · AZD3759 (1) · Pirotinib (1) · Nimotuzumab (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses abivertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedPhase 2Sorrento Therapeutics, Inc.NCT05361915Written as AbivertinibHow we know
- Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedPhase 2Sorrento Therapeutics, Inc.NCT04440007Written as AbivertinibHow we know
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as Avitinib MaleateHow we know
- Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19CompletedPhase 2Sorrento Therapeutics, Inc.NCT04528667Written as STI-5656How we know
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCStatus unknownPhase 1/2Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT02330367Written as AC0010How we know
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung CancerTerminatedPhase 1ACEA Therapeutics, Inc.NCT02448251Written as AC0010MAHow we know
- Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03856697Written as Abivertinib Maleate CapsulesHow we know
- Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCStatus unknownPhase 2Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03300115Written as AC0010How we know
- A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIWithdrawnPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03058094Written as AC0010How we know
- Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 TreatmentCompletedPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03053219Written as AC0010How we know
- A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03060850Written as AC0010MAHow we know
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLCCompletedPhase 1Hangzhou ACEA Pharmaceutical Research Co., Ltd.NCT03001609Written as AC0010How we know
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownPhase 1/2Sun Yat-sen UniversityNCT02274337Written as AC0010How we know
Codes
What other systems call abivertinib · ClinicalTrials.gg INT001074
- MeSH (NLM) C000630672abivertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CER0OPG92LABIVERTINIBConfirmed FDA, NLM
- NCI Thesaurus C147125AbivertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630672 | abivertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CER0OPG92L | ABIVERTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C147125 | Abivertinib | One source FDA |
Also registered as abivertinib maleate (UNII Y50131AMFJ) and abivertinib maleate anhydrous (UNII 0447KM2XTD).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.